Sep 23 |
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
|
Sep 21 |
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
|
Sep 21 |
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
|
Sep 19 |
Teva Pharmaceutical Industries Limited (TEVA) Bank of America Global Healthcare Conference (Transcript)
|
Sep 15 |
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is favoured by institutional owners who hold 68% of the company
|
Sep 13 |
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
|
Sep 11 |
Teva to Present at the Bank of America 2024 Global Healthcare Conference
|
Sep 10 |
Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial
|
Sep 10 |
Sector Update: Health Care Stocks Advance Late Afternoon
|
Sep 10 |
Teva agrees to pay Baltimore City $80m for fuelling opioid epidemic
|